Applied Filters
Fed Circuit split over $235m skinny label verdict
The US Court of Appeals for the Federal Circuit has reinstated a $235 million verdict against Teva in a split decision which could have major implications for skinny label generics.
Shionogi and Duchesnay add new patents to Osphena dispute
Pharmaceutical companies Shionogi and Duchesnay have filed a second lawsuit against Hetero labs, claiming that the company infringed two additional patents related to Osphena—a treatment for vaginal pain during sex.
Takeda faces ‘pay-for-delay’ class-action suit over anti-constipation drug
Takeda Pharmaceuticals is the target of a proposed class action that alleges the pharma giant paid to keep a generic anti-constipation drug off the market.
FDA approves milestone biosimilar insulin drug
The US Food and Drug Administration has approved the first-ever interchangeable biosimilar product, an insulin treatment for Types 1 and 2 diabetes.
AstraZeneca loses major generics appeal in India
The Delhi High Court has cleared the way for a slew of generic diabetes drugs to arrive on the Indian market after it rejected AstraZeneca’s request for a blocking order.
CMA fines drugmakers £260m for 10,000% price hike
The UK’s Competition and Markets Authority has imposed fines of £260 million on drug companies for raising the price of life-saving hydrocortisone tablets by 10,000%.
POTUS orders crackdown on anticompetitive drug practices
An executive order by President Joe Biden has targeted anti-competitive practices in the US drugs market, including a ban of pay-for-delay agreements.
Taiwanese biotech built on ‘foundation of lies’, says DoJ
US prosecutors have charged the founders of Taiwanese biosimilar manufacturer JHL Biotech with stealing Genentech trade secrets.
Teva sues two Indian generics over Huntington’s treatment
Teva Pharmaceuticals has filed lawsuits in New Jersey against two Indian generics manufacturers to stop them from developing a generic version of its Huntington’s disease treatment.
UK Supreme Court shoots down NHS £220m drug patent suit
The UK Government has failed to convince UK Supreme Court judges that Servier Laboratories misrepresented its blood pressure drugs patent in legal proceedings to block generic competitors from entering the market.
